MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 9 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Clinical management and resolution of stomatitis in BOLERO-2.
Alejandra Perez, Hope S. Rugo, José Baselga, Lowell L. Hart, Kathleen I. Pritchard, Francis P. Arena +14 more
2013· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’
Dennis J. Slamon, Patrick Neven, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Sun-Wha Im +14 more
2021· erratum· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
3
citations
aboutno affunlabeled
Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS
Meghan Karuturi, Gabrielle B. Rocque, Joseph C. Cappelleri, Joanne L. Blum, Steven McCune, Bijoy Telivala +8 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
3
citations
affno abstractunlabeled
395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Kyung Hae Jung, Stephen J. Luen, Mafalda Oliveira, Joohyuk Sohn, S-A Im, Seth A. Wander +10 more
2023· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
3
citations
fundno affno abstractunlabeled
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
Andrew D.J. Pearson, Susan Chi, Theodore W Laetscht, Lynley V. Marshall, Elizabeth A. Raetz, Rani E. George +32 more
2025· review· en· European Journal of Cancer· Medicine
distilled prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
Richard S. Finn, Karen A. Gelmon, Johannes Ettl, Jamil Asselah, Aurelio Castrellon, A. Simon +6 more
2017· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
3
citations
affunlabeled
Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with <i>PIK3CA</i> mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
Komal Jhaveri, Dejan Juric, Andréa Varga, Nicholas C. Turner, Peter Schmid, Cristina Saura +14 more
2021· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
3
citations
affno abstractunlabeled
Academic research sheds light on issues that matter to patients
Martine Piccart, Isabelle Gingras
2016· review· en· Nature Reviews Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · research_integrity+insufficient_payload
2
citations
affunlabeled
Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292
Erika Hamilton, Patrick Neven, Barbara Pistilli, Muralidhar Beeram, Virginia F. Borges, Mario Campone +12 more
2024· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
2
citations
affunlabeled
Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.
Massimo Cristofanilli, Angela DeMichele, C. Giorgetti, Dennis J. Slamon, Seock‐Ah Im, Norikazu Masuda +7 more
2017· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
2
citations
affunlabeled
Abstract PS11-11: Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with <i>PIK3CA</i>-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
Mafalda Olivera, Komal Jhaveri, Dejan Juric, Philippe L. Bédard, Andrés Cervantes, Valentina Gambardella +12 more
2021· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
2
citations
← previousnext →

How this was built: Screen · Findings · About